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Helicobacter pylori was first isolated by Warren and Marshall in 1982. 
It is a Gram-negative bacterium found on the gastric epithelium and 
induces chronic inflammation of the underlying mucosa. H. pylori 
infection is usually contracted in the first few years of life and tends 
to persist indefinitely unless treated. It is the most common cause of 
chronic gastritis and peptic ulcer disease and a risk factor for gastric 
adenocarcinoma and mucosa-associated lymphoid tissue lymphoma. 
First-line eradication triple therapy comprises a proton pump 
inhibitor (PPI) and two of the following antibiotics: clarithromycin, 
metronidazole and amoxicillin.1,2
However, consensus on the length of treatment is lacking. 
European practitioners considered 7 days of treatment sufficient to 
achieve a high eradication rate, in contrast to the USA, where a more 
consistent eradication rate was obtained by prolonging the duration 
of therapy to 14 days.1,2 Antibiotic resistance is a major cause of 
treatment failure.3 The prevalence of antimicrobial resistance in H. 
pylori varies regionally within and between countries. Increasing the 
duration of treatment or providing alternative antibiotics based on 
local resistance rates may improve eradication rates.4 Widespread and 
indiscriminate use of antibiotics in developing countries has resulted 
in a higher prevalence of resistance than in industrialised countries.5
The Maastricht III Consensus Guidelines state that effective 
eradication treatment should be successful in more than 80% of 
intention-to-treat (ITT) and 90% of per protocol (PP) treated 
patients, and that local studies should be done to establish the 
duration of treatment and eradication rates.1 In Kenya the first-line 
treatment is a PPI, amoxicillin and clarithromycin, but the optimal 
duration of therapy remains controversial. As we are not aware of 
local published studies to establish the rate of H. pylori eradication 
with the triple therapy and with different treatment periods, we 
decided to determine the optimum duration of triple therapy for H. 
pylori eradication.
Methods
All patients who presented between December 2009 and May 2010 
with dyspepsia and who were positive for H. pylori on stool antigen 
tests were enrolled. Exclusion criteria were: previous attempts at 
H. pylori eradication, intake of bismuth, H2-antagonists, PPIs, or 
antibiotics within the 3 months prior to entry to the study, a history 
of intolerance and/or allergy to the study drugs, pregnancy or 
lactation, and alarm features. Alarm features were defined as age >45, 
gastrointestinal bleeding, anaemia, early satiety, unexplained weight 
loss, progressive dysphagia, odynophagia, recurrent vomiting, a family 
history of gastrointestinal cancer, and previous oesophagogastric 
malignancy.2 The study was approved by the local Ethics Committee 
and informed, written consent was obtained from each patient.
This was a prospective randomised investigator-blind comparative 
trial of 7- and 14-day triple therapy for H. pylori eradication 
conducted at the Aga Khan University Hospital, Nairobi. All patients 
who presented with dyspepsia and who were H. pylori-positive 
on stool antigen testing were randomised by simple computer-
generated randomisation to receive either 7-day or 14-day triple 
therapy (esomeprazole 20 mg twice a day, amoxicillin 1 g twice a 
day, clarithromycin 500 mg twice a day). After 2 weeks the patients 
were reviewed by the principal investigator for assessment of side-
effects and compliance. A stool antigen test was repeated 6 weeks 
after the start of therapy to confirm eradication of H. pylori.
The patients were not charged for reviews at 2 and 6 weeks 
and a free H. pylori stool antigen test was performed to confirm 
eradication. Patients who still had H. pylori at 6 weeks were referred 
to the gastroenterology clinic for second-line therapy.
Hypothesising a difference of 20% between eradication rates 
achieved by the two regimens, and fixing a statistical power of at least 
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Background. Helicobacter pylori is associated with several upper 
gastrointestinal conditions including chronic gastritis, peptic ulcer 
disease, and gastric malignancy. Proton pump inhibitor-based 
triple therapies are considered the standard regimens for H. pylori 
eradication, but the optimal duration of therapy is controversial. 
To prevent infection and complications, local studies should be 
undertaken to evaluate H. pylori eradication rates in a country.
Objectives. We compared 7-day and 14-day regimens to determine 
the optimum duration of triple therapy for H. pylori eradication.
Methods. We undertook a prospective randomised comparative 
trial of 7-day and 14-day triple therapy regimen for H. pylori 
eradication at the Aga Khan University Hospital, Nairobi; 120 
patients with dyspepsia and H. pylori infection were randomised 
to receive esomeprazole, amoxicillin and clarithromycin for either 
7 days (EAC 7) or 14 days (EAC 14). Compliance and side-effects 
were assessed 2 weeks after the start of therapy and H. pylori 
eradication was assessed by stool antigen tests 4 weeks after 
treatment.
Results. Both the intention-to-treat (ITT; N=120) and per 
protocol (PP; N=97) analyses showed no significant differences 
between the eradication rates of EAC 7 (ITT 76.7%; PP 92%) and 
EAC 14 (ITT 73.3%; PP 93.6%) (ITT p=0.67; PP p=0.76). Poor 
compliance was reported in one patient in the EAC 14 group. The 
incidence of adverse events was comparable in the two groups.
Conclusion. One-week and 2-week triple treatments for H. pylori 
eradication are similar in terms of efficacy, safety and patient 
compliance.
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80% with a value of α<0.05, we calculated the minimal number of 
patients to be included in each group (1 week or 2 weeks) to be 46. 
With an estimated drop-out rate of 30%, we then needed 120 patients 
in total and 60 patients in each group.
Compliance was assessed by counting the pills returned by the 
patients and was considered adequate with an intake >90% of the 
drugs prescribed. The type and severity of adverse events during 
treatment were reported by patients on diary cards, to be returned no 
later than 1 week after ending therapy. Adverse effects were defined as 
mild when not interfering with normal daily activity; moderate when 
frequently interfering but allowing treatment to be completed, and 
severe when withdrawal was necessary.6
Data were analysed using SPSS version 15.0. Analysis of baseline 
characteristics and eradication success between different treatment 
protocols were performed using the chi-square test. The t-test was 
used to analyse the age distribution between the patient groups. Data 
were analysed according to ITT and PP criteria. The ITT analysis 
included all patients randomised to a treatment group, whereas in the 
PP analysis patients lost during follow-up or showing low compliance 
were excluded. The incidence and severity of adverse events in the 
two groups were also compared using the chi-square test.
Results
During December 2009 and May 2010, 146 patients with H. pylori-
positive dyspepsia were identified. Of these, 26 were excluded: 
21 did not meet inclusion criteria and 5 did not give consent. Of 
the 21, 3 were pregnant, 4 were breastfeeding, 3 were allergic to 
penicillin, 6 had used PPIs within 4 weeks of presentation, and 4 
had alarm features. The patients with alarm features were booked 
for endoscopy and follow-up in the gastroenterology clinic. Patients 
who did not give consent were given appropriate standard therapy. 
Remaining for enrolment and randomisation were 120 patients; 
60 were randomised to receive esomeprazole 20 mg twice daily in 
combination with amoxicillin 1 g twice daily and clarithromycin 
500 mg twice daily for 1 week (EAC 7) and 60 the same regimen for 
2 weeks (EAC 14).
In the 7-day group 10 patients were lost to follow-up; 3 had 
travelled out of the city, 2 could not be reached by telephone and 5 did 
not see the benefit of coming back as they were asymptomatic. All the 
patients in the 7-day group were >90% compliant (Fig. 1).
In the 14-day group 12 patients were lost to follow-up; 4 had 
travelled out of the city, 2 could not be reached by telephone and 6 did 
not see the benefit of coming back as they were asymptomatic. One 
patient in the 14-day group was not compliant.
All patients were considered for ITT analysis, but only 97 for PP 
analysis, 23 patients (19.2%) having being excluded because they had 
been lost to follow-up (n=22) or showed poor compliance (n=1).
The mean age was in the fourth decade with no statistically 
significant difference between the two groups, and men and women 
were equally represented. Homogeneity in the basic demographic 
data allowed the two groups to be comparable.
Only 7 patients (5.8%) were smokers and 43 (35.8%) had a history 
of alcohol consumption. The difference in distribution of participants 
between the EAC 7 and EAC 14 groups was not significant for either 
smoking or alcohol consumption, with p-values of 0.24 and 0.85 
respectively. Smoking is an independent risk factor for H. pylori 
treatment failure.7 In contrast, alcohol consumption may facilitate 
elimination of H. pylori infection among adults.8
All patients who had dyspepsia and were referred for endoscopy 
had H. pylori-positive gastritis. Patients with histology-proven H. 
pylori-positive gastritis were equally distributed between the two 
groups (Table 1).
Compliance was good; 97 of the participants (98.98%) had a 
compliance of >90% and only 1 (1.02%) had <90% compliance. 
However, 22 (18.3%) were lost to follow-up. The only patient who had 
less than 90% compliance was in the EAC 14 group. We postulated 
that compliance was good because all patients were informed about 
the importance of H. pylori eradication and the possible drug side-
effects before commencing therapy. Bacterial resistance and poor 
patient compliance are believed to be the primary factors in H. pylori 
treatment failure. The occurrence of side-effects can reduce the 
compliance with treatment regimens and lead to the development of 
bacterial resistance.9
In the EAC 7 group 10 patients (16.7%) were lost to follow-up 
whereas in the EAC 14 group 12 (20%) were lost to follow-up, but 
Table 1. Baseline characteristics of study patients
EAC 7 (N=60) EAC 14 (N=60) p-value
Gender
Male 25 (41.7%) 24 (40%) 0.85
Female 35 (58.3%) 36 (60%)
Age (yrs) mean 
(SD)
34 (10) 36 (11) 1.0
Smoking
Yes 5 (8.3%) 2 (3.3%) 0.24
No 55 (91.7%) 58 (96.7%)
Alcohol
Yes 21 (35%) 22 (36.7%) 0.85
No 39 (65%) 38 (63.3%)
Endoscopy
Not done 49 (81.7%) 47 (78.3%) 0.65
Gastritis 11 (18.3%) 13 (21.7%)
Compliance
>90% 50 (100%) 47 (97.9%) 0.53
<90% 0 1 (2.1%)
Lost to follow-up 10 (16.7%) 12 (20%) 0.24
Fig. 1. Flow of participants through each phase of the study and incidence 
of patients lost to follow-up and with low compliance. PPI = proton pump 
inhibitor; ITT = intention to treat; PP = per protocol; EAC 7 = esomeprazole 
20 mg, amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days; 
EAC 14 = esomeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg 
twice daily for 14 days.
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again the difference is not significant (p=0.24). Most of the patients 
who did not come for follow-up visits felt better after the treatment.
Eradication rates
Our objective was to determine and compare the H. pylori eradication 
rates between 7- and 14-day triple therapy regimens according to 
the ITT and the PP analysis. All patients were considered for ITT 
analysis, but only 97 for PP analysis. The 23 patients (19.2%) excluded 
were lost to follow-up (n=22) or showed poor compliance (n=1). On 
ITT analysis EAC 7 eradication rates were 76.7% (95% confidence 
interval (CI) 66 - 87.4%) whereas for EAC 14 the eradication rates 
were 73.3 % (95% CI 62.1 - 84.5%). The difference between the two 
groups was not statistically significant (p=0.67).
On PP analysis, the eradication rate in the EAC 7 group was 92% 
(95% CI 84.5 - 99.5%), which was slightly lower than the 93.6% 
achieved in the EAC 14 group (95% CI 86.6 - 100%), but was not 
significant (p =0.76).
There was no significant difference between EAC 7 and EAC 14 
regimens in either the ITT (p=0.67) or the PP (p=0.76) analysis. The 
difference in eradication rates between the EAC 7 and EAC 14 groups 
was -3.4% in the ITT analysis and 1.6% in the PP analysis (Table 2).
Gender, smoking habit, alcohol consumption and prior endoscopy 
had no influence on eradication rates, but our study was not powered 
for this conclusion. These factors were equally distributed in both 
groups and therefore unlikely to have significantly influenced the 
results.
Compliance and tolerability
Compliance was analysed in 98 patients, after exclusion of the 22 
patients lost to follow-up. Compliance was found to be inadequate 
(intake of <90% of total tablets) in 1 patient (1.02%). Compliance 
was good in 97 (98.98%) of the participants. However, 22 (18.3%) 
were lost to follow-up. Compliance was comparable in both groups 
100% in the EAC 7 group and 97.9% in the EAC 14 group (p=0.53). 
The only patient who had <90% compliance was in the EAC 14 
group. Ten patients in the EAC 7 group (16.7%) were lost to follow-up 
whereas 12 patients (20%) in the EAC 14 group were lost to follow-up 
(p=0.24).
Possible adverse effects of the regimen were headache, nausea, 
vomiting, diarrhoea, loss of appetite, taste disturbance, abdominal 
pain and rash. Taste disturbance was the commonest adverse effect; 
17 (34%) were affected in EAC 7 group and 25 (53.2%) in the EAC 14 
group (p=0.057). All adverse events were mild and did not necessitate 
withdrawal or interfere with therapy. There was no statistically 
significant difference in the experience of side-effects between the 
treatment groups.
Discussion
International guidelines have allowed consensus on the best 
management and improved eradication rates of H. pylori. Therapy 
regimens and their duration could not be standardised because 
clinical data and efficacy of therapy vary between countries. 
This variation in the results could be due to factors such as 
bacterial virulence, environmental factors and widespread use 
of antibiotics. Increasing antimicrobial resistance has resulted in 
falling eradication rates with standard therapies.10 The first-line 
treatment remains clarithromycin, amoxicillin or metronidazole 
and a PPI twice daily, but recent studies show low eradication 
rates, and increased duration of therapy has been recommended to 
overcome this. There have been conflicting findings on the benefits 
of extending the length of traditional therapy.2 European guidelines 
indicate that triple therapy for 1 week is acceptable whereas, 
in the USA, 10 - 14 days of treatment is preferred.1,2 Regional 
antimicrobial resistance and eradication rates should determine the 
best treatment for H. pylori.1
No data or consensus about the duration of treatment for H. pylori 
in Kenya were available. Therefore we evaluated the triple therapy 
of esomeprazole 20 mg twice a day, amoxicillin 1 g twice a day and 
clarithromycin 500 mg twice a day in the first randomised controlled 
study comparing the efficacy of 1 and 2 weeks of triple therapy for 
H. pylori eradication in patients in Kenya. We found that 1 week 
of treatment with esomeprazole, clarithromycin and amoxicillin 
achieved H. pylori eradication rates of 76.7% and 92% by ITT and PP 
analyses, respectively. Extending the treatment to 2 weeks does not 
enhance eradication rates (73.3% and 93.6% by ITT and PP analyses, 
respectively). The difference between eradication rates achieved with 
1 and 2 weeks of triple therapy is not statistically significant.
Studies of PPI-based triple therapy for 7 days, mainly from 
European countries, confirm that this remains a valid duration for 
H. pylori treatment.11 Our results are consistent with recent studies 
such as the HYPER study12 from Italy, which was a large, multicentre, 
double-blind and randomised study comparing the efficacy of 1- and 
2-week regimens of omeprazole, amoxicillin and clarithromycin. 
Their ITT (N=907) and PP (N=661) analyses showed no significant 
differences between the eradication rates at 1 week (ITT 79.7%; PP 
83.6%) and 2 weeks (ITT 81.7%; PP 84.9%) (ITT p=0.53; PP p=0.71). 
Laine et al.13 reported that ITT eradication percentages with triple 
therapy (omeprazole, amoxicillin and clarithromycin) were 86% 
at 7 days, 90% at 10 days and 92% at 14 days in a study at a single 
institution. A multicentre study in 11 centres in Asia and Africa, 
where patients with endoscopy-proven duodenal ulcer and who 
were H. pylori-positive were treated with clarithromycin 500 mg, 
omeprazole 20 mg, and amoxicillin 1 000 mg, all given twice daily for 
7 days, recruited a total of 117 patients. Overall, H. pylori eradication 
rates were 85% by PP analysis and 80% by ITT analysis. Only 25 
patients were from South Africa, where eradication rates were 86% 
(19/22) (95% CI 65.1 - 97.1%) by PP analysis and 76% (19/25) (95% 
CI 54.9 - 90.6%) by ITT analysis.14 These results are in keeping with 
our study.
Clinicians must stress the importance of taking the medications 
as prescribed to minimise the likelihood of antibiotic resistance 
developing, as this is a major cause of treatment failure. The 
prevalence of antimicrobial resistance in H. pylori shows regional 
variation within and between countries. Clarithromycin resistance 
Table 2. H. pylori eradication rates calculated according to 
ITT and PP analysis
Regimen EAC 7 EAC 14 p-value
No. of patients 60 60
Lack of compliance 0 1
Lost to follow-up 10 12
H. pylori eradicated 46 44
ITT analysis (n)
% eradicated
(95% CI)
46/60
76.7%
(66 - 87.4)
44/60
73.3%
(62.1 - 84.5)
0.67
PP analysis (n)
% eradicated
(95% CI)
46/50
92%
(84.5 - 99.5)
44/47
93.6%
(86.6 - 100)
0.76
ITT = intention to treat; PP = per protocol; EAC 7 = esomeprazole 20 mg, amoxicillin 1 g 
and clarithromycin 500 mg twice daily for 7 days; EAC 14 = esomeprazole 20 mg, amoxicillin 
1 g and clarithromycin 500 mg twice daily for 14 days.
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varies significantly, ranging from close to zero up to 25% and has 
significant impact on eradication success, but bacterial resistance 
to amoxicillin is <1% in most countries.1 Alternative antibiotics 
based on local resistance rates may improve eradication rates. The 
widespread and indiscriminate use of antibiotics in developing 
countries has resulted in a higher prevalence of resistance than in 
industrialised countries.5
One week of triple therapy remains the recommended first line 
treatment for H. pylori eradication12 in regions where primary 
resistances of clarithromycin or metronidazole are lower than 15 - 
20% or 40%, respectively.
Data on H. pylori antibiotic sensitivity profiles in Kenya are 
scarce, a recent study showing all H. pylori largely sensitive to 
clarithromycin (100%), amoxicillin (100%) and metronidazole 
(95.4%). There was, however, occasional resistance to metronidazole 
(4.6%).15 This confirms our finding that 7-day triple therapy is 
adequate for H. pylori eradication because local resistance rates are 
very low.
No serious adverse events were documented in either treatment 
group. The adverse events were mild and did not necessitate 
withdrawal or interfere with therapy. There was no statistically 
significant difference in the side-effects between the treatment 
groups. The tolerability of triple therapy has been good and similar 
for 1- and 2-week regimens.12
Compliance with antimicrobial therapy is better with short- 
duration therapy. This is particularly relevant with H. pylori 
eradication regimens because side-effects such as diarrhoea or taste 
disturbance can lead to discontinuation of therapy in some patients, 
with potential treatment failure. All our patients were educated on 
the importance of H. pylori eradication and possible side-effects, 
with the result that patient compliance was high.
In conclusion, this study shows that the efficacy and safety of 
1 week of triple therapy including esomeprazole with amoxicillin 
and clarithromycin does not differ significantly from 2 weeks of 
treatment for the eradication of H. pylori.
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